RNA Strangle Strategy
RNA (Atrium Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
RNA (Atrium Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $208.2M, a beta of 0.37 versus the broader market, a 52-week range of 11.13-16.77, average daily share volume of 202K, a public-listing history dating back to 2026, approximately 511 full-time employees. These structural characteristics shape how RNA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.37 indicates RNA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on RNA?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
RNA snapshot
As of August 14, 2026, spot at $13.14, ATM IV 18.60%, IV rank 10.50%, expected move 5.33%. The strangle on RNA below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 154-day expiry.
Why this strangle structure on RNA specifically: RNA IV at 18.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a RNA strangle, with a market-implied 1-standard-deviation move of approximately 5.33% (roughly $0.70 on the underlying). The 154-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RNA expiries trade a higher absolute premium for lower per-day decay. Position sizing on RNA should anchor to the underlying notional of $13.14 per share and to the trader's directional view on RNA stock.
RNA strangle setup
The RNA strangle below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RNA at $13.14 on that close, the first option leg uses a $13.80 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RNA chain at a 154-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RNA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $13.80 | N/A |
| Buy 1 | Put | $12.48 | N/A |
RNA strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
RNA strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on RNA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on RNA
Strangles on RNA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the RNA chain.
RNA thesis for this strangle
The market-implied 1-standard-deviation range for RNA extends from approximately $12.44 on the downside to $13.84 on the upside. A RNA long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current RNA IV rank near 10.50% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on RNA at 18.60%. As a Healthcare name, RNA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RNA-specific events.
RNA strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RNA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RNA alongside the broader basket even when RNA-specific fundamentals are unchanged. Always rebuild the position from current RNA chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on RNA?
- A strangle on RNA is the strangle strategy applied to RNA (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With RNA stock at $13.14 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed RNA chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are RNA strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the RNA strangle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 18.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a RNA strangle?
- The breakeven for the RNA strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The RNA market-implied 1-standard-deviation expected move in the same options snapshot is approximately 5.33%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on RNA?
- Strangles on RNA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the RNA chain.
- How does current RNA implied volatility affect this strangle?
- RNA ATM IV is at 18.60% with IV rank near 10.50%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.